Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Eukaryotic translation elongation factor 1 epsilon-1 (EEF1E1) is a multifunctional, non-enzymatic protein that serves primarily as an auxiliary component of the macromolecular aminoacyl-tRNA synthetase complex in the cytoplasm, facilitating translational elongation during protein synthesis[2][5]. In response to DNA damage, its mouse homolog can translocate to the nucleus and positively modulate ATM/ATR-mediated p53 activation, implicating a role in cellular stress responses and genome stability[2][6]. EEF1E1 has also been linked to human diseases such as Robinow syndrome and has been associated with cancer via its involvement in cell proliferation and the DNA damage response pathway[2]. While it is crucial for protein synthesis machinery function, there are no approved or experimental drugs known to target EEF1E1 directly, nor is it considered a receptor, enzyme, or common therapeutic target[2][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Eukaryotic translation elongation factor 1 epsilon-1 (EEF1E1).